Dr. Andy Golden at NIH discusses his work on identifying regulators and interactors of conserved genes in C. elegans that, when mutated, can cause human disease and opportunities to use C. elegans as a model in clinical and translational research.
News & Events
NemaMetrix and Knudra Transgenics announce merger to provide fast genotype-to-phenotype answers. The combined company will operate under NemaMetrix Inc.
As a young and growing company, we are trying to design and introduce new products that can better serve your research needs. We’d like to share what we are working on. Sign up for notification and win a cool t-shirt.
NemaMetrix, a company developing nematode-based drug development and screening technologies, announced the launch of its first series of RediStain™ fluorescent kits for improved visualization of C. elegans’ structure and function in phenotyping studies. These kits expand the toolkit of C. elegans research to include the ability to perform structural and functional assays that are standard in cell biology.
NemaMetrix Inc. was selected as the only company representing the state of Oregon by the Science Coalition in its latest Sparking Economic Growth reports released Apr 25, 2017.